Although structured as a merger in which NextCure is the legal acquirer, the economic substance of this transaction is a reverse merger — Avere, a private company, is using NextCure's public company infrastructure (Nasdaq listing, SEC reporting status, registered shares) to access public capital markets without conducting a traditional IPO.

The ownership split makes this clear: Avere shareholders and PIPE investors will hold approximately 98–99% of the combined company, while existing NextCure shareholders will hold approximately 1–2% (subject to net cash adjustments). Management and the board of directors will be determined by Avere. The combined company will carry Avere's name and ticker.

This structure — sometimes called a SPAC-alternative or reverse merger with PIPE — has become a common pathway for well-capitalized private biotechs seeking public market access with greater certainty of funding than a traditional IPO provides.

The approximately $320 million in concurrent financing consists of two components:

Convertible note conversion (~$251 million). Existing convertible notes issued to Avere's pre-merger investors convert into shares of the combined company at closing. This is not new cash — it represents the conversion of previously committed capital into equity at the merger closing.

New PIPE investment. The remainder of the $320 million represents new cash investment from PIPE participants at closing. The merger agreement requires that at least $150 million in PIPE financing be available at closing as a condition to the transaction.

Hansoh Pharmaceutical is identified as a lead investor in the $320 million financing — the same party that licensed AVR-001 to Avere and received a $120 million upfront payment. Hansoh's participation as both licensor and investor creates an aligned incentive structure: Hansoh benefits from Avere's development success both through milestone and royalty payments and through equity appreciation.

The combined company's primary asset is AVR-001, an oral small-molecule inhibitor of IL-23 in development for:

• Psoriasis — Phase 2b results anticipated; Phase 3 initiation planned
• Ulcerative colitis — Phase 2b study planned

Mechanism and market context. IL-23 is a cytokine that plays a central role in the pathogenesis of psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The IL-23 pathway is validated by multiple approved biologics (risankizumab/Skyrizi, guselkumab/Tremfya, tildrakizumab/Ilumya). AVR-001's differentiation thesis is oral administration — current approved IL-23 inhibitors are injectable biologics. A once-weekly oral IL-23 inhibitor, if it achieves comparable efficacy and safety, would represent a significant convenience advantage for patients and a potential market share opportunity against the injectable standard of care.

Hansoh license terms:

• Upfront payment: $120 million (paid by Avere to Hansoh for ex-China rights)
• Development and sales milestones: Up to $2.18 billion
• Royalties: Applicable on net sales

The license covers development and commercialization rights outside China — Hansoh retains China rights.

The transaction is structured as a two-step merger under Delaware law:

1. First merger: A merger subsidiary merges with and into Avere, with Avere surviving as a wholly owned subsidiary of NextCure
2. Second merger: Avere merges with and into NextCure (or a subsidiary), with the surviving entity becoming the operating company

This two-step structure is standard in public company acquisitions and provides flexibility for managing the timing of share issuance, regulatory filings, and the PIPE closing.

Tax treatment. The transaction is intended to qualify as a tax-free reorganization under IRC §368(a). If the reorganization qualifies, Avere shareholders will not recognize gain or loss on the exchange of their Avere shares for NextCure/AVRX shares. The IRC §368(a) qualification requires, among other things, that the transaction satisfy continuity of interest and continuity of business enterprise requirements — the PIPE financing structure and the post-closing ownership split are designed with these requirements in mind.

Existing NextCure shareholders face severe dilution — their ownership will fall to approximately 1–2% of the combined company. To partially preserve the value of NextCure's legacy oncology portfolio for existing shareholders, the transaction includes a contingent value right (CVR):

• Entitlement: 90% of net proceeds from future licensing or sale of NextCure's pre-merger oncology assets
• Non-transferable: CVRs remain with the NextCure shareholders of record at closing
• Contingent: Whether any payment is made depends entirely on whether the oncology assets are successfully monetized

This CVR structure mirrors the approach used in other reverse merger and carve-out transactions (including the Ligand/XOMA transaction announced the same day) to bridge the gap between the acquirer's valuation of legacy assets and the seller's desire to preserve optionality.

Form S-4. The combined company must file a registration statement on Form S-4 with the SEC covering the shares to be issued to Avere shareholders and PIPE investors. The S-4 will include a proxy statement/prospectus for the NextCure shareholder vote. SEC review of the S-4 typically takes 30–60 days, with potential comment letters extending the timeline.

In connection with the merger, NextCure announced a workforce reduction affecting the majority of its employees. The company expects to incur approximately $1.9 million in severance and transition costs. This restructuring reflects the reality that the combined company's operations will be driven by Avere's team and programs — NextCure's existing workforce is largely redundant in the post-merger structure.

HSR filing. The transaction may require Hart-Scott-Rodino premerger notification depending on the size of the transaction and the parties' revenues. Biotech reverse mergers with PIPE financing frequently fall below HSR thresholds or qualify for the research and development exemption, but this requires case-specific analysis.

SEC review. The Form S-4 registration statement will be subject to SEC staff review. Common SEC comments in biotech reverse merger S-4s include:

• Clinical data disclosure and risk factor adequacy
• Related-party transaction disclosure (Hansoh as licensor and investor)
• Pro forma financial statement presentation
• CVR accounting treatment

ULF New York monitors U.S. life sciences and biopharma M&A transactions. This update is prepared for informational purposes and does not constitute legal advice. For transaction-specific M&A, securities law, or licensing counsel, contact our New York office.